GGrantIndex
← Leaderboards

Sally Margaret Blower

University Of California San Francisco

$13,847,923
Attributed
$13,847,923
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.2M · FY200524
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$13,847,923 · 7

By mechanism

R01$11,868,027 · 3
R56$1,134,436 · 2
R21$845,460 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of California San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Mathematical Model

Research focus

Mathematical ModelEpidemicBaseAcquired Immunodeficiency SyndromeHiv InfectionsDesignTransmission ProcessDrug ResistanceResourcesCountryHealthcareInterruptionIncidenceData SetGrantPrevalenceAfricaProgramsAfricanPublic Health RelevancePreventLinkHealth PolicyFuture

Grant awards (27)

Using geospatial science to maximize the opportunity to access ART in Africa$773,130
R01 · FY2024 · AI · contact PI
Using geospatial science to maximize the opportunity to access ART in Africa$961,184
R01 · FY2023 · AI · contact PI
Using geospatial science to maximize the opportunity to access ART in Africa$789,860
R01 · FY2022 · AI · contact PI
Helping Botswana Achieve UNAIDS Treatment Targets to End Its HIV Epidemic$644,436
R56 · FY2020 · AI · contact PI
Optimal Strategies for HIV Treatment and Prevention in Sub-Saharan Africa$599,281
R01 · FY2019 · AI · contact PI
Optimal Strategies for HIV Treatment and Prevention in Sub-Saharan Africa$598,511
R01 · FY2018 · AI · contact PI
Optimal Strategies for HIV Treatment and Prevention in Sub-Saharan Africa$598,511
R01 · FY2017 · AI · contact PI
Optimal Strategies for HIV Treatment and Prevention in Sub-Saharan Africa$598,511
R01 · FY2016 · AI · contact PI
Optimal Strategies for HIV Treatment and Prevention in Sub-Saharan Africa$299,181
R01 · FY2015 · AI · contact PI
Determining whether TasP could eliminate HIV in resource-rich countries$154,000
R21 · FY2015 · AI · contact PI
HIV - Emergence of Drug Resistance$490,000
R56 · FY2014 · AI · contact PI
Determining whether TasP could eliminate HIV in resource-rich countries$269,500
R21 · FY2014 · AI · contact PI
HIV - Emergence of Drug Resistance$670,826
R01 · FY2012 · AI · contact PI
HIV - Emergence of Drug Resistance$695,913
R01 · FY2011 · AI · contact PI
Designing optimal interventions to control HIV in Africa using data-based models$152,460
R21 · FY2011 · AI · contact PI
HIV - Emergence of Drug Resistance$713,348
R01 · FY2010 · AI · contact PI
Designing optimal interventions to control HIV in Africa using data-based models$269,500
R21 · FY2010 · AI · contact PI
HIV - Emergence of Drug Resistance$230,969
R01 · FY2010 · AI · contact PI
HIV - Emergence of Drug Resistance$724,023
R01 · FY2009 · AI · contact PI
HIV - Emergence of Drug Resistance$736,294
R01 · FY2008 · AI · contact PI
HIV--Emergence of Drug Resistance$569,660
R01 · FY2006 · AI · contact PI
HIV--Emergence of Drug Resistance$577,515
R01 · FY2005 · AI
HIV--Emergence of Drug Resistance$573,556
R01 · FY2004 · AI
HIV--Emergence of Drug Resistance$567,089
R01 · FY2003 · AI
HIV--Emergence of Drug Resistance$317,799
R01 · FY2002 · AI
HIV, TB, HSV 2--EMERGENCE OF DRUG RESISTANCE$219,993
R01 · FY2000 · AI
HIV, TB, HSV 2--EMERGENCE OF DRUG RESISTANCE$52,873
R01 · FY2000 · AI